{"entity":{"id":"nct07870096","kind":"trial","name":"ITR-251 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of ITR-251 run by ITERIA BIOPHARMA, S.L., not yet recruiting.","summary":"ITR-251 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT07870096 by ITERIA BIOPHARMA, S.L., with 46 participants planned, started 2026-10. Conditions recorded: Solid Tumor Cancer and Castration Resistant Metastatic Prostate Cancer. Interventions recorded: ITR-251, ITR-251 at RP2D, ARPI therapy and Androgen Deprivation Therapy (ADT).","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07870096","url":"https://clinicaltrials.gov/study/NCT07870096"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["itr-251"],"companies":["iteria-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07870096","phase":"1","setting":"Phase I/Ib Trial of Single Agent ITR-251 in Patients With Advanced Solid Tumors With an Expansion-Phase in Metastatic Castration-Resistant Prostate Cancer","sponsor":"ITERIA BIOPHARMA, S.L.","enrolled":46,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07870096/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"itr-251","kind":"drug","name":"ITR-251","route":"/drugs/itr-251/"}],"company":[{"id":"iteria-biopharma","kind":"company","name":"Iteria Biopharma","route":"/companies/iteria-biopharma/"}]}}